Integer Q3 Sales Fall 3.9% to $450M, Adjusted EPS Down 25% Ahead of KKR Close
ITGR has more than doubled off its 52-week low of $62.
Summary
Integer reported a weak third quarter — sales down 3.9% to $450M and adjusted EPS down 25% to $1.34 — with no guidance or call while its $127-per-share KKR buyout works toward a year-end close.
Updates
· Reuters — Integer Holdings Q3 sales fell 3.9% to $450 mln, missing the $457.15 mln consensus estimate of 10 analysts, and Q3 adjusted EPS of $1.34 missed the $1.69 estimate.
- Other Markets sales decline attributed to exit from Portable Medical segment
- Cardiac Rhythm Management & Neuromodulation growth partially offset by impact from new Neuromodulation product
- Q3 adjusted net income $46 mln, missing $58.06 mln consensus of 8 analysts
Key Events · Earnings and Guidance · ITGR
-
Q3 Sales Fall 3.9% to $450M
Sales were $449.7M versus $467.7M a year ago; organic sales fell 2.2% after excluding the Portable Medical exit.
-
Profitability Contracts Sharply
GAAP operating income fell 50% to $28.2M and adjusted EPS dropped 25% to $1.34 from $1.79, with adjusted EBITDA down 17% to $87.9M.
-
Cardio & Vascular Drag
Cardio & Vascular sales fell 5.1% to $263.1M on the two new Electrophysiology products, partly offset by 3.9% growth in Cardiac Rhythm Management & Neuromodulation to $175.8M.
-
Leverage at 3.3x Adjusted EBITDA
Total debt rose $34M from year-end 2025 to $1.219B, leaving net total debt of $1.223B and a 3.3x leverage ratio.
Analysis · ITGR · Industrial Applications And Services
The third quarter deteriorated across the board: sales fell 3.9% to $449.7M, GAAP operating income halved to $28.2M, and adjusted EPS dropped 25% to $1.34. Weakness is concentrated in Cardio & Vascular, down 5.1% on the two new Electrophysiology products, while the neuromodulation franchise grew 3.9%. With the $127-per-share KKR buyout already agreed and approved by stockholders, the numbers matter less for valuation than for deal risk: a softer operating base and 3.3x leverage give any financing or closing condition less cushion. Because guidance and the earnings call were suspended, this release is the last substantive look at the business before the deal is expected to close by year-end 2026.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ITGR was trading at $126.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $62.00 to $126.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.